Although these compounds were originally selected for their ability to inhibit Tdp1 catalysis and modeled-docking of the compounds into the Tdp1 catalytic pocket, the more current and promising compounds were tested in combination with DNA Topo1 inhibitors (topotecan or irinotecan) in cell and xenograft mouse models of cancer. The gene discussed is TDP1; the disease is cancer.